Precision BioSciences (NASDAQ:DTIL) CEO Michael Amoroso Sells 34,799 Shares

Precision BioSciences, Inc. (NASDAQ:DTIL) CEO Michael Amoroso sold 34,799 shares of the stock in a transaction dated Thursday, January 22nd. The shares were sold at an average price of $4.17, for a total transaction of $145,111.83. Following the completion of the transaction, the chief executive officer directly owned 196,154 shares in the company, valued at approximately $817,962.18. This represents a 15.07% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink.

Michael Amoroso also recently made the following trade(s):

• On Monday, November 3rd, Michael Amoroso sold 3,409 shares of Precision BioSciences stock. The shares were sold at an average price of $6.49, for a total value of $22,124.41.

Precision BioSciences Price Performance

Shares of NASDAQ DTIL opened at $4.25 on Friday. The firm has a market cap of $56.36 million, a P/E ratio of -0.51 and a beta of 1.20. The business’s 50 day moving average is $4.59 and its 200-day moving average is $5.12. The company has a current ratio of 3.45, a quick ratio of 3.45 and a debt-to-equity ratio of 1.35. Precision BioSciences, Inc. has a 1-year low of $3.75 and a 1-year high of $8.82.

Precision BioSciences (NASDAQ:DTIL) last posted its quarterly earnings data on Monday, November 3rd. The company reported ($1.84) earnings per share for the quarter, missing the consensus estimate of ($0.31) by ($1.53). The firm had revenue of $0.01 million for the quarter, compared to the consensus estimate of $5.40 million. Precision BioSciences had a negative return on equity of 233.77% and a negative net margin of 11,977.36%.During the same quarter in the previous year, the business earned ($2.25) EPS. Equities research analysts predict that Precision BioSciences, Inc. will post -1.23 earnings per share for the current year.

Hedge Funds Weigh In On Precision BioSciences

Institutional investors have recently modified their holdings of the company. Geode Capital Management LLC grew its position in Precision BioSciences by 5.5% in the 2nd quarter. Geode Capital Management LLC now owns 77,712 shares of the company’s stock valued at $326,000 after purchasing an additional 4,025 shares during the period. Lynx1 Capital Management LP boosted its holdings in Precision BioSciences by 0.6% during the third quarter. Lynx1 Capital Management LP now owns 1,042,596 shares of the company’s stock worth $5,755,000 after purchasing an additional 6,545 shares during the last quarter. Vanguard Personalized Indexing Management LLC purchased a new position in Precision BioSciences during the third quarter worth about $72,000. Virtu Financial LLC bought a new stake in Precision BioSciences in the 3rd quarter worth about $84,000. Finally, GSA Capital Partners LLP purchased a new stake in Precision BioSciences in the 3rd quarter valued at about $98,000. 37.99% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Precision BioSciences in a report on Monday, December 22nd. One equities research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, Precision BioSciences presently has a consensus rating of “Hold” and an average target price of $60.00.

About Precision BioSciences

Precision BioSciences is a clinical‐stage genome editing company that leverages its proprietary ARCUS platform to develop targeted gene therapies. ARCUS, an engineered nuclease derived from a naturally occurring enzyme, enables precise DNA modifications for both in vivo and ex vivo applications. The company’s pipeline spans genetic diseases—including rare monogenic disorders—and immuno‐oncology, where it is advancing allogeneic cell therapy candidates designed to address hematologic malignancies and solid tumors.

Founded in 2006 as a spin‐out from research at the University of North Carolina, Precision BioSciences is headquartered in Durham, North Carolina, with additional research and manufacturing capabilities located in the Research Triangle Park area.